Sandoz【0SAN】銘柄情報

Sandoz Group AG (0SAN) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

( - )

買値

0.00

売値

0.00

出来高

448,429

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

前日終値

0.00

始値

時刻

67.40674

(O)

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

CHF 687,047

発行済株式数

432,692,617

配当利回り

1.01

PER

40.3

1 株当たり利益 (EPS)

2.09

歳入

11.16B

純利益

914M

Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neu... Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland. 詳細を表示

セクター

業界

ウェブサイト

www.sandoz.com

本社

Basel, Switzerland

設立

1886

Sandoz Group AG is listed in the sector of the ロンドン証券取引所 with ticker 0SAN. The last closing price for Sandoz was CHF0. Over the last year, Sandoz shares have traded in a share price range of CHF 0.00 to CHF 0.00.

Sandoz currently has 432,692,617 shares in issue. Sandoz has a price to earnings ratio (PE ratio) of 40.30.

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations MEDIA RELEASE Sandoz signs 10-year...

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter Ad hoc announcement pursuant to art. 53 SIX Swiss...

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in...

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market...

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million...

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars MEDIA RELEASE Pyzchiva® first...

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed Ad-hoc announcement pursuant to art. 53 SIX Swiss...

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications...

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG All proposals of Board of...

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US Ad hoc announcement...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0SAN - Frequently Asked Questions (FAQ)

What is the current Sandoz Group AG share price?

The current share price of Sandoz Group AG is CHF 0.00

How many Sandoz Group AG shares are in issue?

Sandoz Group AG has 432,692,617 shares in issue

What is the 1 year trading range for Sandoz Group AG share price?

Sandoz Group AG has traded in the range of CHF 0.00 to CHF 0.00 during the past year

What is the PE ratio of Sandoz Group AG?

The price to earnings ratio of Sandoz Group AG is 40.3

What is the cash to sales ratio of Sandoz Group AG?

The cash to sales ratio of Sandoz Group AG is 3.27

What is the registered address of Sandoz Group AG?

The registered address for Sandoz Group AG is Centralbahnstrasse 4, Basel, Basel-Stadt, 4051

What is the Sandoz Group AG website address?

The website address for Sandoz Group AG is www.sandoz.com

100lbStriper 6分前

Netlist demands ban on Samsung HBM and DRAM in the US https://www.sammyfans.com/2026/06/20/netlist-demands-ban-on-samsung-hbm-and-dram-in-the-us/#google_vignette

NLST

100lbStriper 8分前

2 weeks old, nlst gets plugged at about 3:50 on the clip....... https://www.youtube.com/watch?v=bX8m2ibc94k

NLST

tkg 10分前

Amazon Braket launches new 54-qubit superconducting quantum processor from IQM
by Zia Mohammad, Charunethran Panchalam Govindarajan, Peter Komar, and Stefan Seegerer on 21 JUL 2025 in Amazon Braket, Quantum Technologies Permalink

Amazon Braket enables customers to design and

LWLG

Bngo 13分前

Great find Makai!Elite made the list!
84% confidence
ROE: 32.9%Debt/Equity: 0.02xNet Margin: 24.4%Rev Growth: 48.4%
Best Growth Stocks to Buy 2026
Updated June 21, 2026 • Authored by MarketsHost Research • AI-reviewed by Claude (Anthropic) + ChatGPT (OpenAI)
Th

ELTP

100lbStriper 19分前

Stokd $NLST #2 Think of it as 4 angles / parts to Netlist litigation:

1) ITC — 2 actions (1 investigation instituted / 1 new complaint pending).

2) Appeals — 3 District Court TX cases on completed trials/wins & PTAB decisions on the patents involved currently at CAF

NLST

100lbStriper 20分前

Stokd $NLST #1 I'll update the litigation chart with new ITC & District Court action, but essentially:

Netlist's focus (aside Micron) is on ITC, with Dist Crt infringement cases on patents litigated at ITC as back up should the need to litigate continue if ITC does not award injunct

NLST

brazen22 21分前

The right answer may be the simplest one.

If this is minutia, then the minutia is that MHRA has not approved because the MAA has not yet satisfied MHRA.

Not BP. Not skeptics. Not market makers. Not message board posters. Not me. Not conferences. Not expanded labels.

NWBO

100lbStriper 23分前

Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest https://www.federalregister.gov/documents/2026/06/22/2026-12369/notice-of-receipt-of-complaint-solicitation-of-comments-relating-to-the-public-interest

NLST

EZ2 24分前

97-54-71-45. 🙏

tkg 35分前

Truly an absolute standout individual to have on board as a Director...now with a quantum angle added to the mix!

Ciesla is an accomplished innovator and product development leader with a proven track record and is an inventor of more than 100 patents and patent applications. He most

LWLG

tkg 52分前

IQM Quantum Computers (founded in 2018, headquartered in Finland) is a global leader in building full-stack, on-premises superconducting quantum computers. They design their own processor chips and provide systems for research labs, high-performance computing centers (HPC), and enterprises worldwide

LWLG

tkg 1時間前

Dr. Craig Ciesla joining IQM Quantum Computers as Chief Technology Officer (CTO) is a notable positive driver for Lightwave Logic, Inc. (NASDAQ: LWLG). As an independent director on the Lightwave Logic Board of Directors, his elevated visibility and influence in the quantum computing ecosystem offer

LWLG

joe_techi 1時間前

Wall Of Voodoo - Me And My Dad
https://www.youtube.com/watch?v=lWvPoamMIwQ

Investor2014 1時間前

Many of the core criticisms are directionally supported by later events and primary documents, but the report also uses inflammatory language, overstates some legal conclusions, conflates Alzheimer's and Rett syndrome at points, and treats negative interpretations as established facts.

AVXL

Investor082 2時間前

Gary,

This is a nice post to go into the record books, LOL! We will check in every quarter to measure progress.

The only problem is you, Flipper, and other minions predicted $23+ share price back in 2022. 4 years later, the two of you and other minions have missed by

NWBO

Investor082 2時間前

While the shareholders got decimated and will continue to get destroyed going forward, LOL! ;)

Any update on the 10 year survival data for NICE?

NWBO

eagle8 2時間前

Doc logic,

we have already seen and read many discussions about the costs NICE is willing/able to pay for DCvax.
If you look at the NEW costs for NICE after approval for DCvax, surely you can state:
Chemo expenses are being minimized and DCvax is being introduced.

NWBO

Tdl9586 2時間前

are you going to vote ? and how are you going to vote ?

TLSS

Seminole Red 2時間前

theres alot of big names on the board, I dont think its going to matter unless Clark Chokes and 2 or 3 others step up.....as Fitz should say, 'Dont fall down like me....

Kam8 2時間前

HI Skitahoe

The most important thing is LP prepared 900M share suddenly.

I am praying BP would pay $8+ for those 900shares.

Or MRK acquire nwbo with $30 Billion suddenly. (Merger)

NWBO

rocketeer357 2時間前

That rent on Freddy is way too high. And the roles are reversed. We're the team that guts farm systems by trading players in their walk year. You're one of the teams that trades the farm for the walk year guys. We can't afford to pay players 20 million plus per year if they don't play. You can and d

fuagf 3時間前

He being a decent wind player as we read, he just had a bad day, is all.

Seminole Red 3時間前

Henly is a top fairway hitter too and strings pars forever, usually .... theres no trees on this course to block the wind

fuagf 3時間前

Yep. On Henley though, as thought could be;

Russell Henley is widely regarded as one of the best wind and adverse-condition players on the PGA Tour.

https://www.google.com/search?q=pga+stats+-+how+is+henley+in+the+wind+&client=firefox-b-d&hs=rwRV&sca_esv=77e9a8666bf485

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Sandoz Group AG (0SAN)

Sandoz Group AG (0SAN) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

Sandoz Group AG について

0SAN 最新ニュース

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

0SAN - Frequently Asked Questions (FAQ)

0SAN 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Sandoz Group AG (0SAN)

Sandoz Group AG (0SAN) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

Sandoz Group AG について

0SAN 最新ニュース

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

0SAN - Frequently Asked Questions (FAQ)

0SAN 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE